KR20080067654A - 폐포성 횡문근육종에서 사용하기 위한 스타우로스포린유도체 - Google Patents

폐포성 횡문근육종에서 사용하기 위한 스타우로스포린유도체 Download PDF

Info

Publication number
KR20080067654A
KR20080067654A KR1020087011406A KR20087011406A KR20080067654A KR 20080067654 A KR20080067654 A KR 20080067654A KR 1020087011406 A KR1020087011406 A KR 1020087011406A KR 20087011406 A KR20087011406 A KR 20087011406A KR 20080067654 A KR20080067654 A KR 20080067654A
Authority
KR
South Korea
Prior art keywords
lower alkyl
formula
hydrogen
radicals
typically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087011406A
Other languages
English (en)
Korean (ko)
Inventor
마르코 와흐텔
베아트 베. 샤퍼
랄프 암스투츠
Original Assignee
유니베르시태트 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니베르시태트 취리히 filed Critical 유니베르시태트 취리히
Publication of KR20080067654A publication Critical patent/KR20080067654A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087011406A 2005-11-14 2006-11-13 폐포성 횡문근육종에서 사용하기 위한 스타우로스포린유도체 Ceased KR20080067654A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73622205P 2005-11-14 2005-11-14
US60/736,222 2005-11-14

Publications (1)

Publication Number Publication Date
KR20080067654A true KR20080067654A (ko) 2008-07-21

Family

ID=37758863

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011406A Ceased KR20080067654A (ko) 2005-11-14 2006-11-13 폐포성 횡문근육종에서 사용하기 위한 스타우로스포린유도체

Country Status (10)

Country Link
US (1) US7973032B2 (cg-RX-API-DMAC7.html)
EP (1) EP1951255A1 (cg-RX-API-DMAC7.html)
JP (1) JP5308820B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080067654A (cg-RX-API-DMAC7.html)
CN (1) CN101304749A (cg-RX-API-DMAC7.html)
AU (1) AU2006313724B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2629478C (cg-RX-API-DMAC7.html)
RU (1) RU2443421C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007054579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132479A1 (en) * 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
CA2253608A1 (en) * 1996-05-01 1997-11-06 Louis Vignati Therapeutic treatment for vegf related diseases
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
RU2269315C2 (ru) * 2004-05-24 2006-02-10 Рашид Кямиль Оглы Гусейнов Способ соединения сосудов и устройство для герметизации надреза сосуда и перерезания стенки сосуда

Also Published As

Publication number Publication date
CN101304749A (zh) 2008-11-12
JP2009515858A (ja) 2009-04-16
US7973032B2 (en) 2011-07-05
EP1951255A1 (en) 2008-08-06
CA2629478C (en) 2013-10-15
US20080280880A1 (en) 2008-11-13
RU2443421C2 (ru) 2012-02-27
WO2007054579A1 (en) 2007-05-18
BRPI0618571A2 (pt) 2011-09-06
JP5308820B2 (ja) 2013-10-09
CA2629478A1 (en) 2007-05-18
AU2006313724A1 (en) 2007-05-18
AU2006313724B2 (en) 2010-12-23
RU2008123382A (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
EP1441737B1 (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2004244747B2 (en) Staurosporine derivatives for hypereosinophilic syndrome
AU2004262927B2 (en) Combinations comprising staurosporines
US7973032B2 (en) Staurosporine derivatives for use in alveolar rhabdomyosarcoma
US20080207496A1 (en) Organic compound
AU2005313556B2 (en) Use of staurosporine derivatives for the treatment of multiple Myeloma
WO2006021456A1 (en) Combination comprising a staurosporine and a cyp3a4 inhibitor
WO2008043811A1 (en) Staurosporine derivatives and radiation
MX2008006287A (es) Derivados de estaurosporina para utilizarse en rabdomiosarcoma alveolar.
AU2008202050A1 (en) Combinations comprising staurosporines
AU2008201869A1 (en) Staurosporine derivatives for hypereosinophilic syndrome
HK1068262B (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080513

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130513

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140303

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130513

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I